Kura Oncology’s (KURA) “Buy” Rating Reiterated at HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $32.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 82.65% from the stock’s current price.

KURA has been the subject of a number of other reports. JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, UBS Group initiated coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Stock Performance

Shares of KURA opened at $17.52 on Wednesday. The company has a 50-day simple moving average of $18.95 and a 200-day simple moving average of $20.02. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.34 billion, a PE ratio of -7.86 and a beta of 0.86. Kura Oncology has a 52-week low of $8.17 and a 52-week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04. The company’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the company posted ($0.53) earnings per share. Equities research analysts predict that Kura Oncology will post -2.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KURA. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares during the period. Avoro Capital Advisors LLC increased its position in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after acquiring an additional 870,000 shares during the period. Armistice Capital LLC boosted its position in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the period. Artal Group S.A. lifted its holdings in Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after purchasing an additional 151,828 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after buying an additional 577,732 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.